Last updated: April 24, 2026
EP2470526 (European Patent Office): Scope, Claims, and Drug Patent Landscape
EP2470526 is a European patent family member of a drug-related technology and sits within a crowded European prosecution and grant landscape. The effective scope and claim boundaries depend on the granted claim set and the validated national equivalents in force in each EPC contracting state. Without the underlying publication text (WO/EP publication number variants, granted specification, and claim amendments during examination), a complete, accurate claim-by-claim scope map cannot be produced from available context alone.
What is EP2470526’s exact drug-invention scope?
EP2470526’s drug patent scope can be broken into four layers that must be derived from the published specification and the granted/validated claim set:
- Active pharmaceutical ingredient (API) definition (chemical entity vs Markush group, salts, solvates, polymorphs).
- Compositions (formulations, excipients, concentration ranges, dosage forms).
- Therapeutic uses (indication claims, patient population, dosing regimens).
- Manufacturing/processing (process claims that can materially extend enforcement beyond composition use).
A scope analysis must tie each of these layers to the exact claim language in EP2470526 as granted (or as amended if opposition changed scope). With only the EPO publication identifier and no claim text, enforcement-relevant elements cannot be enumerated.
What do EP2470526’s claims cover (claim-by-claim)?
A claim-by-claim map requires the following from the EP specification:
- Independent claim set (usually 1 or 2 claims).
- Dependent claim structure (which variations narrow coverage).
- Any product-by-process elements (if present).
- Any fallback positions added during prosecution or preserved post-opposition.
Without the claim text (claims 1..N, numbering as published and numbering as granted), the following key deliverables cannot be produced accurately:
- A definitive list of protected product features.
- A definitive list of protected use/dosing features.
- The minimum claim coverage required to establish infringement.
- The design-around risk based on dependent-claim narrowing.
How does EP2470526 position in the European patent landscape?
Even with an identified EP family member, the competitive landscape requires:
- The family tree (priority date(s), related WO publication, continuation filings).
- Status by member state (granted, refused, lapsed, revoked, limited, or stayed).
- Opposition history at the EPO (if any), including maintenance of claims or amendments.
- Citation and overlap with earlier or co-pending patents in the same therapeutic area:
- Same API chemical space.
- Same formulation space.
- Same indication space.
- Same dosing/regimen space.
- Later patent “evergreening” that may narrow or compete (new polymorphs, salts, particle sizes, combination products, new dosing).
None of these facts can be reliably derived from the identifier alone in a way that meets a professional patent analysis standard.
Key enforcement and valuation levers that require the claim text
What is the legal scope that determines enforcement in Europe?
For drug patents in Europe, the highest-value scope elements are:
- Composition claims (API entity and salt/solvate/polymorph boundaries).
- Medical use claims (Article 54(5) style second medical use or Swiss-type format where applicable).
- Dose regimen claims (fixed dosing windows or titration schedules).
- Process claims (especially if they define manufacturing steps uniquely).
A correct scope conclusion must quote or tightly paraphrase the claim features. That cannot be done without the published/granted text.
Where do challengers typically attack scope in the EPO?
In European practice, opposition arguments often target:
- Novelty against earlier disclosures.
- Inventive step based on closest prior art plus obvious modifications.
- Added subject matter if claims were amended.
- Clarity and support for broad Markush groups, ranges, and functional features.
- Enablement where embodiments are not sufficiently exemplified.
A landscape assessment must map these typical attack points onto the exact claim structure of EP2470526. Claim text is essential.
Practical landscape view you can use once the claims are extracted
This section is the template used for EP drug patent landscape work. It is presented in a deterministic format, but it cannot be populated with EP2470526-specific numbers, dates, and claim elements without the EP record content.
Competitive “adjacent” IP buckets to check
For EP drug patents, the most material overlaps usually fall into four buckets:
- Same API / different salt/solvate/polymorph (exacts scope depends on claim grammar).
- Same formulation / different excipient system or particle size.
- Same indication / different dosing or patient stratification.
- Combination therapy (often claims shift from monotherapy composition to co-administered regimens).
What a full landscape deliverable includes
A complete EPO landscape deliverable for EP2470526 includes:
- Family and priority chain with dates.
- Claim coverage matrix by independent and dependent claims.
- Opposition and limitation outcomes (if any).
- For each relevant competitor patent:
- publication number
- priority date
- grant status in key states
- claim overlap category (API, formulation, use, process)
Key Takeaways
- EP2470526’s scope and claims cannot be accurately analyzed to a claim-by-claim enforcement conclusion without the underlying EP publication/granted claim text and legal status record.
- A correct European drug patent landscape requires family-tree data, opposition outcomes, and in-force status by state, plus citation/overlap mapping to earlier and later filings.
- The deliverables that business teams use for freedom-to-operate and portfolio valuation (claim feature coverage, design-around paths, and competitor overlap) depend on the exact wording and post-prosecution claim set.
FAQs
1) What determines EP drug patent scope in Europe most directly?
The exact wording of the granted (or maintained) claims defining composition, medical use, dosing regimen, and any product-by-process limitations.
2) Why does the opposition outcome matter to enforcement?
EPO opposition can narrow or replace claim scope via amendments, materially changing infringement risk and licensing leverage.
3) How is EP drug patent landscape overlap typically categorized?
By API form (salt/solvate/polymorph), formulation (composition and particle/excipient parameters), therapeutic use (indication), and dosing/process.
4) What is the most common “design-around” strategy?
Targeting the specific claim-limiting feature (e.g., a defined salt/polymorph, a dose window, or an excipient or manufacturing step) once those features are known from the claims.
5) What sources should be used to build the EP2470526 landscape?
The EPO publication and register (EP/WO documents, granted texts, and legal status), plus the cited prior art in the prosecution history.
References
[1] European Patent Office. EP publication and register for EP2470526 (publication, application, and legal status records).
